COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,437 Articles (22,835 medRxiv, 8,602 bioRxiv)

Most recent first Previous |  Page 141: Articles 1401-1410  | Next

Quantifying the impact of the COVID-19 pandemic on the Scottish accident and emergency landscape.
Pheng Teoh, H., Banas, K., Oldnall, C. A.
10.1101/2024.12.20.24319411 — Posted: 2024-12-21
Impact of COVID-19 vaccine doses and viral waves on inflammatory and immunological responses to COVID-19 infections in India
Sharma, K. K., Pratap, U., Marathe, Y., Shaikh, S., D Costa, P., Gupta, G., Wang, M., Fawzi, W. W., Kain, K. C., Mistry, N., Dholakia, Y.
10.1101/2024.12.19.24319150 — Posted: 2024-12-21
Changes in Female Cancer Diagnostic Billing Rates over the COVID-19 Period in the Ontario Health Insurance Plan
McLeod, D., Martins, I., Tinker, A. V., Selk, A., Brezden-Masley, C., LeVasseur, N., Altman, A.
10.1101/2024.12.17.24319153 — Posted: 2024-12-20
A Large Language Model Guides the Affinity Maturation of Variant Antibodies Generated by Combinatorial Optimization
Ashraf, F. B., Zhang, Z., Paco, K., Mendivil, M. P., Lay, J. A., Ray, A., Lonardi, S.
10.1101/2024.12.19.629473 — Posted: 2024-12-20
Nebulized 2-deoxylated glucose analogues inhibit respiratory viral infection in advanced in vitro airway models
Wideman, S. K., Wali, L. K., Kovtunyk, V., Chou, S., Gussel, V., Telimaa, H., Najmi, C., Stoeva, D., Stoeckl, J., Gualdoni, G. A., Gorki, A.-D., Radivojev, S.
10.1101/2024.12.20.629606 — Posted: 2024-12-20
Study of the immunogenicity, efficacy and safety of recombinant RBD SARS-CoV-2 vaccine with CpG adjuvant in rodent, non-rodent and Maccaca fascicularis using Indonesian Strain Virus
Limeilati, N. A., Nidom, R. V., Sari, T. T., Kusumarahayu, N. P., Fransiska, S. V., Indrasari, S., Garmana, A. N., Ayuningtyas, D. K., Nugroho, G. S., Darsono, , Maharani, , Wijayadikusumah, A. R., Sukandar, E. Y., Nidom, A. N., Adnyana, I. K., Nurainy, N., Nidom, C.
10.1101/2024.12.18.629000 — Posted: 2024-12-20
Quantitative Characterization and Prediction of the Binding Determinants and Immune Escape Hotspots for Groups of Broadly Neutralizing Antibodies Against Omicron Variants: Atomistic Modeling of the SARS-CoV-2 Spike Complexes with Antibodies
Alshahrani, M., Parikh, V., Foley, B., Raisinghani, N., Verkhivker, G.
10.1101/2024.12.19.629520 — Posted: 2024-12-20
T-ALPHA: A Hierarchical Transformer-Based Deep Neural Network for Protein-Ligand Binding Affinity Prediction With Uncertainty-Aware Self-Learning for Protein-Specific Alignment
Kyro, G. W., Smaldone, A. M., Shee, Y., Xu, C., Batista, V. S.
10.1101/2024.12.19.629497 — Posted: 2024-12-20
Integrated analysis of COVID-19 multi-omics data for eQTLs reveals genetic mechanisms underlying disease severity
Lee, J., Jeon, E. Y., Yu, L., Jo, H.-Y., Kim, S. C., Park, W.-Y., Park, H.-Y., Zhao, S., Choi, M.
10.1101/2024.12.18.629144 — Posted: 2024-12-20
Establishment of a Chikungunya virus pseudotype system strictly dependent on viral protein expression
Tanaka, A., Miyazawa, T.
10.1101/2024.12.19.629062 — Posted: 2024-12-20

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).